111 related articles for article (PubMed ID: 16434088)
1. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
Masters GR; Berger MA; Albone EF
Gynecol Oncol; 2006 Sep; 102(3):462-7. PubMed ID: 16434088
[TBL] [Abstract][Full Text] [Related]
2. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft.
Remmenga SW; Colcher D; Gansow O; Pippen CG; Raubitschek A
Gynecol Oncol; 1994 Oct; 55(1):115-22. PubMed ID: 7959251
[TBL] [Abstract][Full Text] [Related]
6. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ
Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
DeNardo SJ; Kukis DL; Miers LA; Winthrop MD; Kroger LA; Salako Q; Shen S; Lamborn KR; Gumerlock PH; Meares CF; DeNardo GL
J Nucl Med; 1998 May; 39(5):842-9. PubMed ID: 9591587
[TBL] [Abstract][Full Text] [Related]
10. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
Ng B; Kramer E; Liebes L; Wasserheit C; Hochster H; Blank E; Ceriani R; Furmanski P
Cancer Res; 2001 Apr; 61(7):2996-3001. PubMed ID: 11306478
[TBL] [Abstract][Full Text] [Related]
13. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
Stein R; Juweid M; Zhang CH; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
[TBL] [Abstract][Full Text] [Related]
14. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
[TBL] [Abstract][Full Text] [Related]
15. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
[TBL] [Abstract][Full Text] [Related]
16. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
17. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
19. [Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
DU YF; Luo RC; Li GP; Li AM; Ding XM; Yan X; Huang K
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):460-2. PubMed ID: 18359714
[TBL] [Abstract][Full Text] [Related]
20. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
